Navigation Links
Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
Date:10/1/2011

LAS VEGAS, Oct. 1, 2011 /PRNewswire/ -- This information is being released by SCM:

Dr. Arthur Reingold, witness for the defense in the second hepatitis C trial in Nevada, was called to the stand today offering expert testimony as an epidemiologist. During questioning by the defense, Dr. Reingold testified transference of the deadly virus hepatitis C could have occurred from a lack of hand washing, ungloved hands, bite blocks, biopsy equipment, gowns and aprons, and that cross contamination of bacteria may have occurred on a daily basis. 

(Photo:  http://photos.prnewswire.com/prnh/20111001/LA78785)

When cross examined by lead trial attorney for the plaintiffs, Robert Eglet, Dr. Reingold responded to questions about his testimony concerning transmission of hepatitis C at the Endoscopy Center of Southern Nevada.

"You can not state with certainty or to any reasonable degree of medical probability or have any evidence that the GI techs or any specific person was not wearing gloves, or that ungloved hands were the cause of transmission of the hepatitis C virus, or that the CRNAs were not washing their hands or wearing gowns or aprons that may have served as the source of the transmission of hepatitis C to Anne Arnold?" said Eglet. "No," stated Reingold. So you are not saying that hepatitis C on an apron somehow found its way into the bloodstream of Anne Arnold, Correct?" said Eglet. "Yes," stated Reingold.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Lehigh University leads Department of Defense MURI grant for atomic-scale interphase research
4. Winners of inaugural defense fellowships to further research at NTU
5. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
6. Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defenses Net Zero Energy Initiative
7. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
8. TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs
9. NJIT physicist sees terahertz imaging as ultimate defense against terrorism
10. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
11. UCLA gets $5.5 million from Defense agency to create new rotating microscale motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Cleveleys, UK (PRWEB) , ... ... ... results presented by surgeons at the 2016 annual meeting of the North ... beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, ... recently announced a collaboration with the Heidelberg University Hospital and the German Cancer ... preparation, following the company’s successful launch of its CATS (Capture and Amplification ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. ... Tracey, MD , president and CEO of The ... completed an analysis of how the nervous system regulates ... and develop bioelectronic medicine devices to treat ... Nature Neuroscience . The paper examines ...
(Date:1/14/2017)... ARLINGTON, Va. , Jan. 13, 2017  The ... following statement in response to FDA final guidance ... FDA for its continued leadership in emphasizing the importance ... members are keenly aware of the benefits biosimilars will ... costs.   Yet the portion of the ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
Breaking Biology News(10 mins):